Risk factors and prevention of the acquisition and transmission of glycopeptide-resistant enterococci;Facteurs de risque et prévention de l'acquisition et de la transmission des entérocoques résistants aux glycopeptides

Pathologie Biologie

Volumn 49, Issue 8, 2001, Pages 641-648

  Talon, D ^a   Bertrand, X ^a   Thouverez, M ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Enterococci; Glycopeptide resistance; Selection pressure; Vancomycin

Indexed keywords

CEPHALOSPORIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CONTROLLED STUDY; DISEASE TRANSMISSION; GRAM NEGATIVE INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; REVIEW; RISK ASSESSMENT;

EID: 0034756962     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(01)00225-5     Document Type: Short Survey

References (73)

1. Genetics and mechanisms of glycopeptide resistance in enterococci
2. Drug therapy: Antimicrobial-drug resistance
3. The VanB gene confers various levels of self-transferable resistance to vancomycin in enterococci
4. VanD-type glycopeptide-resistant Enterococcus faecium BM4339
5. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405
6. Enquête nationale de prévalence des infections nosocomiales, 1996
7. Vancomycin-resistant enterococci
8. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993
9. Entérocoques résistants aux glycopeptides: Portage et infection
10. Réseau franc-comtois de lutte contre les infections nosocomiales. Les entérocoques: Épidémiologie dans les hôpitaux de l'est de la France en 1996
11. Risk factors for vancomycin-resistant enterococcal infection and colonization
12. Rapid increase in the prevalence of antimicrobial drug resistance among enterococcal blood isolates in southern Israel
13. Prevalence of colonization with vancomycin-resistant enterococci in various population groups in Berlin, Germany
14. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin
15. The Garrod lecture. The Enterococcus: A classic example of the impact of antimicrobial resistance on therapeutic options
16. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations
17. In-vitro activity of trospectomycin a new aminocyclitol antibiotic against multidrug-resistant Enterococcus faecium
18. Cotransfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
19. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection
20. Nosocomial infection by Staphylococcus haemolyticus and typing methods for epidemiologic study
21. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality
22. Enterococcal bacteremia: Risk factors for vancomycin resistance and predictors of mortality
23. Differences in outcomes for patients with bactermia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
24. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections
25. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: A controlled study
26. Risk factors for mortality with enterococcal bloodstream infections
27. Recommendations for preventing the spread of vancomycin resistance
28. Role of environmental contamination in the transmission of vancomycin-resistant enterococci
29. The role of the hospital environment in the epidemiology of multi-resistant bacteria
30. Antibiotic resistance in hospital organisms and its relation to antibiotic use
31. Is antimicrobial resistance in hospital microorganisms related to antibiotic use?
32. Enterococci and vancomycin resistance
33. The epidemiology of intraveinous vancomycin usage in a university hospital. A 10-year study
34. Antimicrobial use and resistance in eight US hospitals: Complexities of analysis and modeling
35. Vancomycin-resistant Enterococcus faecium in hospitalized children
36. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit
37. Outbreak of multi-drug resistant Enterococcus faecium with transferable vanB class vancomycin resistance
38. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers
39. Outbreak investigation of vancomycin-resistant enterococci: A case-control study
40. Controlling glycopeptide-resistant enterococci
41. Effect of vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecalis
42. Order form for restricting vancomycin prescribing
43. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients
44. Enterococci resistant to multiple antimicrobial agents, including vancomycin: Establishment of endemicity in a university medical center
45. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus
46. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci
47. High-level resistance to gentamicin in Streptococcus faecalis: Risk factors and evidence for exogenous acquisition of infection
48. High-level resistance in Enterococcus faecalis bacteremia
49. Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis
50. Clinical and molecular epidemiology of hospital Enterococcus faecalis isolates in eastern France
51. The duration of fecal carriage of vancomycin-resistant Enterococcus faecium (VREF)
52. Duration of fecal carriage of vancomycin-resistant Enterococcus (VRE) in ICU patients
53. Stool surveillance for vancomycin-resistant Enterococcus faecium (VREF) on a pediatric oncology ward: Duration of shedding and incidence of clinical infections
54. Natural history of colonization with vancomycin-resistant Enterococcus faecium
55. In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants
56. Genetic analysis of a plasmid-encoded, host genotype-specific enhancement of bacterial fitness
57. Adaption to the fitness costs of antibiotic resistance in Escherichia coli
58. Balancing the drug-resistance equation
59. Recommendations for preventing spread of vancomycin resistance, Recommendations of Hospital Infection Control Practices Advisory Committee (HISPAC)
60. Epidemiology, appropriateness and cost of vancomycin use
61. Vancomycin use in a university medical center: Effect of a vancomycin continuation form
62. Vancomycin use in hospital with vancomycin restriction
63. Evaluation of vancomycin use in a pediatric teaching hospital based on CDC criteria
64. Vancomycin control measures at a tertiary-care hospital: Impact of interventions on volume and patterns of use
65. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci
66. Plasmid-mediated vanB glycopeptide resistance in enterococci
67. Epidemiologic analysis of glycopeptide-resistant Enterococcus in neutropenic patients receiving prolonged vancomycin administration
68. Evidence for genetic unrelatedness of nosocomial outbreak of vancomycin-resistant Enterococcus faecium strains in a prediatric hospital
69. Faecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in the Netherlands
70. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients
71. Environmental strains of Enterococcus faecium with inducible high-level resistance to glycopeptides
72. Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farmd
73. Intestinal colonization of a human subject by vancomycin-resistant Enterococcus faecium